New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

alcon laboratories (australia) pty ltd - chondroitin, hyaluronic acid - solution for injection - discovisc® (ovd) is indicated for use during surgery in the anterior segment of the eye. it is designed to create and maintain space, to protect the corneal endothelium and other intra-ocular tissues and to manipulate tissues during surgery.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

alcon laboratories (australia) pty ltd - chondroitin, hyaluronic acid - solution for injection - viscoelastic solution is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction. ophthalmic viscoelastic solutions serve to maintain a deep anterior chamber during anterior segment surgery, thereby reducing trauma to the corneal endothelium and surrounding ocular tissues. they help to push back the vitreous face and prevent formation of a flat chamber postoperatively

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lumos medical pty ltd - 35658 - lens, intraocular, posterior chamber - the device is a posterior chamber intraocular lens suitable for in-the-bag, sulcus or asymmetric fixation and is indicated for primary implantation for the visual correction of aphakia following cataract extraction.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

kevin grundy (ibd) pty ltd - 35658 - lens, intraocular, posterior chamber - an intraocular lens to be implanted permanently in the posterior chamber of the eye to replace the natural cataractous crystalline human eye lens and restore useful vision using an injector

Stati Uniti - Ingliż - NLM (National Library of Medicine)

bpi labs, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 1 mg in 1 ml - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. induction and maintenance of mydriasis during intraocular surgery. none. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. epinephrine crosses the placenta. e

Stati Uniti - Ingliż - NLM (National Library of Medicine)

fresenius kabi usa, llc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol injection, usp is indicated for the following therapeutic uses: • the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.  • the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass.  • the reduction of elevated intraocular pressure when it cannot be lowered by other means.  • the promotion of urinary excretion of toxic substances. mannitol solution, 2.5% is indicated as an irrigation solution in transurethral prostatic resection or other transurethral surgical procedures. • well established anuria due to severe renal disease.  • severe pulmonary congestion or frank pulmonary edema.  • active intracranial bleeding except during craniotomy.  • severe dehydration.  • progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.  • progressive heart failure or pulmonary congestion after mannitol therapy

Stati Uniti - Ingliż - NLM (National Library of Medicine)

remedyrepack inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. induction and maintenance of mydriasis during intraocular surgery. none. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. epinephrine crosses the placenta. epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (fetal anoxia, spontaneous abortion, or both). epinephrine is teratogenic in rabbits, mice, and hamsters dosed during organogenesis. epinephrine has been shown to have teratogenic effects (including gastroschisis and embryonic lethality) when administered subcutaneous in rabbits at approximately 15 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days). in mice, teratogenic effects (including embryonic lethality) were observed at approximately 3 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). these effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). in hamsters, teratogenic effects were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day for 4 days). epinephrine usually inhibits spontaneous or oxytocin induced contractions of the pregnant human uterus and may delay the second stage of labor. avoid epinephrine during the second stage of labor. in dosage sufficient to reduce uterine contractions, the drug may cause a prolonged period of uterine atony with hemorrhage. avoid epinephrine in obstetrics when maternal blood pressure exceeds 130/80 mmhg. use with caution during labor and delivery. although epinephrine improves maternal hypotension associated with anaphylaxis, it may result in uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia. it is not known whether epinephrine is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when epinephrine is administered to a nursing woman. safety and effectiveness of epinephrine in pediatric patients with septic shock have not been established. clinical use data support weight-based dosing for treatment of anaphylaxis in pediatric patients, and other reported clinical experience with the use of epinephrine suggests that the adverse reactions seen in children are similar in nature and extent to those both expected and reported in adults. the safety and effectiveness of epinephrine (at a dilution of 1:100,000 to 1:400,000) for induction and maintenance of mydriasis during intraocular surgery have been established in pediatric patients. use of epinephrine for induction and maintenance of mydriasis during intraocular surgery in pediatric patients is supported by adequate and well controlled studies in adults and uncontrolled studies in pediatric patients. clinical studies of epinephrine for the treatment of hypotension associated with septic shock did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. clinical studies for the treatment of anaphylaxis have not been performed in subjects aged 65 and over to determine whether they respond differently from younger subjects. however, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. therefore, for the treatment of anaphylaxis, consider starting with a lower dose to take into account potential concomitant disease or other drug therapy. for induction and maintenance of mydriasis during intraocular surgery, no overall differences have been observed between elderly and other patients.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

general injectables and vaccines, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - 1.1 hypotension associated with septic shock epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.2 anaphylaxis emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. 1.3 induction and maintenance of mydriasis during intraocular surgery induction and maintenance of mydriasis during intraocular surgery. none. 8.1 pregnancy ri

Emirati Għarab Maqgħuda - Ingliż - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

leader medical device trading united kingdom - 1 intraocular lens - device - n/a - medical devices-medical devices

Stati Uniti - Ingliż - NLM (National Library of Medicine)

henry schein, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - 1.1 hypotension associated with septic shock epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.2 anaphylaxis emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. 1.3 induction and maintenance of mydriasis during intraocular surgery induction and maintenance of mydriasis during intraocular surgery. none. 8.1 pregnancy ri